Paliperidon Ratiopharm® (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidon Ratiopharm®, is a atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It treats schizophrenia in adults and is administered by a healthcare professional.

GNH USA supplies Paliperidon Ratiopharm® as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Paliperidon Ratiopharm® is an atypical antipsychotic that acts on dopamine and serotonin pathways to manage psychotic disorders. - Schizophrenia: Reduces positive and negative symptoms and helps prevent relapse. - Schizoaffective disorder: Stabilises mood and psychotic symptoms. - Bipolar I disorder (adjunct): Assists in mood stabilization when combined with other therapies.

Paliperidone palmitate may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Injection site pain - Headache - Akathisia - Weight gain - Drowsiness - Constipation

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe orthostatic hypotension - Hyperglycaemia - Seizures - Elevated t ​t      ​     t  t  t  t 

Paliperidon Ratiopharm® requires careful monitoring and patient education before and during therapy.

- Assess t  ​  ​  ​   ​       ​   …  ...  -   ...  -  ...  -  … \n""""  "."""  """ " "